A study found that using iGlarLixi therapy is safe and effective for treating diabetes, regardless of whether or not patients are also taking SGLT2 inhibitors. This combination therapy does not pose any additional risks and can help improve outcomes for patients with diabetes. The study emphasizes the importance of using a personalized approach to diabetes treatment and highlights the potential benefits of combining different medications to optimize care. Additionally, the study suggests that this combination therapy can be a valuable option for managing diabetes effectively.
Source link
Advancing therapy with iGlarLixi safe and effective for diabetes treatment irrespective of SGLT2 inhibitors use: Study
